Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BB Biotech AGXSWX:BION +1.55%32 Net Cash per Share is CHF3.60 as of Jun. 2026, which is 100% below its 10-year median of 25.46. GuruFocus rates XSWX:BION with a GF Score™ of 32/100. The stock has 3 warning signs investors should review. Among 801 Biotechnology companies, BB Biotech AG ranks worse than 77.78% on this metric.
The historical rank and industry rank for BB Biotech AG's Net Cash per Share or its related term are showing as below:
XSWX:BION'
s Price-to-Net-Cash Range Over the Past 10 Years
Min: 7.07 Med: 25.46 Max: 27.24
Current: 14.56
During the past 13 years, the highest Price-to-Net-Cash Ratio of BB Biotech AG was 27.24. The lowest was 7.07. And the median was 25.46.
XSWX:BION's Price-to-Net-Cash is ranked worse than 77.78% of 801
companies
in the Biotechnology industry
Industry Median: 4.94
vs XSWX:BION: 14.56
BB Biotech AG (XSWX:BION) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
BB Biotech AG Net Cash per Share Related Terms
BB Biotech AG Net Cash per Share Historical Data
* Premium members only.
The historical data trend for BB Biotech AG's Net Cash per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:BION vs VRTX, REGN, RVMD: Net Cash per Share Comparison
For the Biotechnology subindustry, BB Biotech AG's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BB Biotech AG Price-to-Net-Cash vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BB Biotech AG's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where BB Biotech AG's Price-to-Net-Cash falls into.
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
BB Biotech AG's Net Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BB Biotech AG (XSWX:BION) has a Net Cash per Share of CHF3.60 as of Jun. 2026. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on BB Biotech AG and its competitors. This is 86% below median its historical median of 25.46. Over the past decade, BB Biotech AG's Net Cash per Share has ranged from 7.07 to 27.24. According to the industry distribution chart, BB Biotech AG ranks #623 out of 801 companies in the Biotechnology industry, placing it in the top 77.8%.
Is BB Biotech AG's Net Cash per Share too high?
BB Biotech AG's current Net Cash per Share of CHF3.60 is 86% below median its 10-year median of 25.46. Over the past 10 years, this metric has ranged from a low of 7.07 to a high of 27.24. Based on the distribution chart, BB Biotech AG ranks #623 out of 801 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BB Biotech AG has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does BB Biotech AG's Net Cash per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BB Biotech AG ranks #623 out of 801 companies for Net Cash per Share. This places BB Biotech AG in the lower half of its industry. The industry median Net Cash per Share is 4.94. Historically, BB Biotech AG's own Net Cash per Share has ranged from 7.07 to 27.24 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Cash per Share for a Biotechnology company?
The median Net Cash per Share among Biotechnology companies is 4.94, based on 801 companies in the industry. Companies in the top quartile (top 25%) have a Net Cash per Share significantly above this median, while those in the bottom quartile fall well below. However, Net Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Cash per Share mean?
A high Net Cash per Share can signal that a stock is expensive relative to its fundamentals. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on BB Biotech AG and its competitors. For the Biotechnology industry, the median Net Cash per Share is 4.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BB Biotech AG's current Net Cash per Share is CHF3.60, which is 86% below median its own 10-year median of 25.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BB Biotech AG stock overvalued right now?
BB Biotech AG (XSWX:BION) has a current Net Cash per Share of CHF3.60. The current Net Cash per Share is CHF3.60, which is 86% below median its 10-year median of 25.46. BB Biotech AG's overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Cash per Share calculated?
Net Cash per Share is calculated from a company's financial statements. For BB Biotech AG (XSWX:BION), the current Net Cash per Share is CHF3.60 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BB Biotech AG is a part of the healthcare sector in Switzerland. Its primary activity includes making investments, especially in the biotechnology market, and is one of the investors in the field of biotechnology. The focus of the investments is on those listed companies that focus on the development and marketing of novel drugs with a clear value for the healthcare system. Geographically company operates in the USA, Netherlands, Singapore, Great Britain, Canada, Switzerland, Curacao, and British Virgin Island.
32GF Score
Get the complete analysis for XSWX:BION
Net Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:BION has been successfully added to your 
